Nanoviricides Stock Performance
| NNVC Stock | USD 1.58 0.01 0.63% |
On a scale of 0 to 100, NanoViricides holds a performance score of 7. The company secures a Beta (Market Risk) of 0.69, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NanoViricides' returns are expected to increase less than the market. However, during the bear market, the loss of holding NanoViricides is expected to be smaller as well. Please check NanoViricides' treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to make a quick decision on whether NanoViricides' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NanoViricides are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, NanoViricides exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Dividend Date 2019-09-24 | Last Split Date 2019-09-24 |
1 | The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides Dr. Diwan | 05/22/2025 |
2 | Insider Trading | 05/30/2025 |
3 | Is NanoViricides, Inc. technically bullish or bearish - MarketsMojo | 06/25/2025 |
4 | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 07/14/2025 |
5 | NanoViricides comments on extension of MPox Public Health Emergency NNVC | 07/16/2025 |
6 | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 07/21/2025 |
7 | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387 Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and N... | 07/23/2025 |
8 | What markets is PBPB expanding into Is NanoViricides Inc. stock a good long term investment option - Breakthrough capital growth - jammulinksnews.com | 07/28/2025 |
9 | NanoViricides says NV-397 is weapon necessary for combatting measles NNVC | 07/30/2025 |
| Begin Period Cash Flow | 8.1 M | |
| Total Cashflows From Investing Activities | -156.6 K |
NanoViricides | Build AI portfolio with NanoViricides Stock |
NanoViricides Relative Risk vs. Return Landscape
If you would invest 124.00 in NanoViricides on May 7, 2025 and sell it today you would earn a total of 34.00 from holding NanoViricides or generate 27.42% return on investment over 90 days. NanoViricides is currently generating 0.5405% in daily expected returns and assumes 5.6181% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than NanoViricides, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NanoViricides Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NanoViricides' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NanoViricides, and traders can use it to determine the average amount a NanoViricides' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0962
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NNVC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.62 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average NanoViricides is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NanoViricides by adding it to a well-diversified portfolio.
NanoViricides Fundamentals Growth
NanoViricides Stock prices reflect investors' perceptions of the future prospects and financial health of NanoViricides, and NanoViricides fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NanoViricides Stock performance.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 20.08 M | ||||
| Shares Outstanding | 16.07 M | ||||
| Price To Earning | (6.02) X | ||||
| Price To Book | 2.87 X | ||||
| EBITDA | (7.76 M) | ||||
| Net Income | (8.29 M) | ||||
| Cash And Equivalents | 14.07 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 1.36 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 34.92 X | ||||
| Book Value Per Share | 0.55 X | ||||
| Cash Flow From Operations | (6.32 M) | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 25.55 M | ||||
| Total Asset | 12.82 M | ||||
| Retained Earnings | (139.37 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 24.38 M | ||||
| Current Liabilities | 6.74 M | ||||
About NanoViricides Performance
By analyzing NanoViricides' fundamental ratios, stakeholders can gain valuable insights into NanoViricides' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NanoViricides has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NanoViricides has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.65) | (0.68) |
Things to note about NanoViricides performance evaluation
Checking the ongoing alerts about NanoViricides for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NanoViricides help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NanoViricides is way too risky over 90 days horizon | |
| NanoViricides may become a speculative penny stock | |
| NanoViricides appears to be risky and price may revert if volatility continues | |
| NanoViricides has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NanoViricides currently holds about 14.07 M in cash with (6.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Latest headline from thefly.com: NanoViricides says NV-397 is weapon necessary for combatting measles NNVC |
- Analyzing NanoViricides' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NanoViricides' stock is overvalued or undervalued compared to its peers.
- Examining NanoViricides' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NanoViricides' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NanoViricides' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NanoViricides' stock. These opinions can provide insight into NanoViricides' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |